These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35625782)

  • 1. Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study.
    Dhiman K; Villemagne VL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Blennow K; Zetterberg H; Martins RN; Gupta V
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.
    Dhiman K; Gupta VB; Villemagne VL; Eratne D; Graham PL; Fowler C; Bourgeat P; Li QX; Collins S; Bush AI; Rowe CC; Masters CL; Ames D; Hone E; Blennow K; Zetterberg H; Martins RN
    Alzheimers Dement (Amst); 2020; 12(1):e12005. PubMed ID: 32211500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.
    Mazzeo S; Ingannato A; Giacomucci G; Manganelli A; Moschini V; Balestrini J; Cavaliere A; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Bagnoli S; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Eur J Neurol; 2024 Jan; 31(1):e16089. PubMed ID: 37797300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum.
    Feizpour A; Doré V; Doecke JD; Saad ZS; Triana-Baltzer G; Slemmon R; Maruff P; Krishnadas N; Bourgeat P; Huang K; Fowler C; Rainey-Smith SR; Bush AI; Ward L; Robertson J; Martins RN; Masters CL; Villemagne VL; Fripp J; Kolb HC; Rowe CC
    J Prev Alzheimers Dis; 2023; 10(4):828-836. PubMed ID: 37874105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia.
    Walia N; Eratne D; Loi SM; Li QX; Varghese S; Malpas CB; Walterfang M; Evans AH; Parker S; Collins SJ; Masters CL; Velakoulis D
    J Neurol Sci; 2022 Jan; 432():120088. PubMed ID: 34922179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
    Lehmann S; Schraen-Maschke S; Vidal JS; Blanc F; Paquet C; Allinquant B; Bombois S; Gabelle A; Delaby C; Hanon O;
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
    Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
    Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    Vrillon A; Ashton NJ; Karikari TK; Götze K; Cognat E; Dumurgier J; Lilamand M; Zetterberg H; Blennow K; Paquet C
    J Neurol; 2024 Mar; 271(3):1297-1310. PubMed ID: 37950758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.